Halozyme Therapeutics HALO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $150.05M+27.1% | —— | $175.23M+27.9% | $165.16M+77.1% | $118.1M+53.7% | ||
| $4.22M+57.1% | $3.3M+24.5% | $2.7M+3.8% | $2.7M+3.8% | $2.69M+10.0% | ||
| $16.64M+55.9% | $16.57M+44.6% | $12.16M-3.3% | $12.16M+28.4% | $10.67M+8.1% | ||
| -$3.43M-220% | —— | -$27.35M-9,268% | $7.09M+150% | $2.86M+321% | ||
| —— | $12.18M— | $12.18M— | $12.18M— | $12.18M— | ||
| $19.55M+610% | $90.48M+298% | $29.7M-58.3% | $11.72M-37.1% | -$3.83M+90.0% | ||
| -$27.38M-4,772% | -$18.78M-343% | $1.1M— | $14.54M-32.1% | $586K-98.5% | ||
| -$24.92M-370% | $33.85M-32.6% | -$7.16M+69.1% | -$29.69M-2,377% | $9.22M-50.7% | ||
| $9.11M+82.3% | —— | $20.32M+153% | $36.07M-17.2% | $5M+204% | ||
| $29.51M+66.2% | $23.38M+31.6% | $17.76M0.0% | $17.76M0.0% | $17.76M0.0% | ||
| $2.25M+21.6% | $1.95M+5.7% | $1.86M+0.9% | $1.85M+0.9% | $1.85M+0.9% | ||
| $180.08M+16.8% | $219.03M+22.7% | $178.6M+54.8% | $99.71M+78.7% | $154.22M+19.2% | ||
| $3.74M+294% | $1.43M-53.2% | $3.03M+99.7% | $1.56M-39.5% | $950K-73.2% | ||
| $8.85M-93.7% | $0-100% | $4.96M-98.4% | $102.76M+10.0% | $139.64M-29.7% | ||
| $9M-82.1% | $273.38M+226% | $209.6M+51.9% | $189.11M+250% | $50.17M-58.1% | ||
| —— | $71.22M— | $71.22M— | $71.22M— | $71.22M— | ||
| -$2.88M+96.8% | -$741.79M— | $201.61M+220% | —— | -$90.42M-9.4% | ||
| $1.61M-51.4% | —— | —— | —— | $3.32M+579% | ||
| -$1.61M+51.4% | —— | -$22.4M-221% | -$298.97M-3,253% | -$3.32M-579% | ||
| $175.59M+190% | —— | $357.8M+1,167% | -$114.47M-593% | $60.48M+30.7% | ||
| —— | $2.86M+8.2% | $2.86M+8.2% | $2.86M+8.2% | $2.86M+8.2% | ||
| —— | $33.66M+67.0% | $33.66M+67.0% | $33.66M+67.0% | $33.66M+67.0% | ||
| $30K-98.2% | $96K-96.0% | $357K-88.6% | $1.13M-62.6% | $1.71M-27.7% | ||
| $2.25M+21.6% | $1.95M+5.7% | $1.86M+0.9% | $1.85M+0.9% | $1.85M+0.9% | ||
| $29.51M+66.2% | $23.38M+31.6% | $17.76M0.0% | $17.76M0.0% | $17.76M0.0% | ||
| -$214K+15.4% | -$271K-32.8% | -$170K+52.0% | -$257K+11.1% | -$253K-15.0% | ||
| -$3.43M-220% | —— | -$27.35M-9,268% | $7.09M+150% | $2.86M+321% | ||
| $9.11M+82.3% | —— | $20.32M+153% | $36.07M-17.2% | $5M+204% | ||
| —— | $71.22M— | $71.22M— | $71.22M— | $71.22M— | ||
| —— | $71.94M— | $71.94M— | $71.94M— | $71.94M— | ||
| $710K— | —— | —— | —— | $0— | ||
| —— | $180.56M+82.6% | $180.56M+82.6% | $180.56M+82.6% | $180.56M+82.6% | ||
| $9M-82.1% | —— | $209.6M+51.9% | $189.11M+250% | $50.17M-58.1% | ||
| —— | $1.37M— | $1.37M— | $1.37M— | $1.37M— | ||
| $170K+78.9% | —— | —— | $637K+184% | $95K-92.4% | ||
| —— | $33.66M+67.0% | $33.66M+67.0% | $33.66M+67.0% | $33.66M+67.0% | ||
| $176.34M+15.0% | $217.6M+24.0% | $175.57M+54.2% | $98.15M+84.4% | $153.27M+21.8% | ||
| $176.34M+15.0% | $217.6M+24.0% | $175.57M+54.2% | $98.15M+84.4% | $153.27M+21.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Halozyme Therapeutics generate?
- Halozyme Therapeutics (HALO) generated $677.4M in operating cash flow over the trailing twelve months.
- What is Halozyme Therapeutics's free cash flow?
- After $9.8M of capital expenditures, Halozyme Therapeutics's free cash flow was $667.7M over the trailing twelve months, up 34.7% year over year.
- Where does Halozyme Therapeutics's cash flow data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
